$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000094480920000039 Filed on October 29, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q4
Revenue	$494.7M	$428.1M	$224.3M
YoY Change	120.5%	87.11%	1.12%
Cost Of Revenue	$318.7M	$272.8M	$142.3M
YoY Change	123.96%	92.25%	-4.82%
Gross Profit	$175.9M	$155.3M	$82.10M
YoY Change	114.25%	78.71%	13.55%
Gross Profit Margin	35.56%	36.28%	36.6%
Selling, General & Admin	$101.8M	$99.90M	$79.10M
YoY Change	28.7%	24.03%	-12.31%
% of Gross Profit	57.87%	64.33%	96.35%
Research & Development	$17.50M	$18.49M	$23.00M
YoY Change	-23.91%	-38.39%	-30.93%
% of Gross Profit	9.95%	11.91%	28.01%
Depreciation & Amortization	$20.10M	$21.04M	$22.50M
YoY Change	-10.67%	-11.63%	-5.86%
% of Gross Profit	11.43%	13.55%	27.41%
Operating Expenses	$445.3M	$406.1M	$336.8M
YoY Change	32.22%	51.66%	8.0%
Operating Profit	-$269.4M	$21.94M	-$254.7M
YoY Change	5.78%	-156.24%	6.32%
Interest Expense	-$5.500M	-$6.000M	-$5.100M
YoY Change	7.84%	9.09%	54.55%
% of Operating Profit		-27.35%
Other Income/Expense, Net	$2.100M	-$1.290M	$9.100M
YoY Change	-76.92%	-93.84%	-212.35%
Pretax Income	$45.90M	$20.65M	-$108.4M
YoY Change	-142.34%	-134.45%	6.9%
Income Tax	$13.60M	-$3.178M	$3.400M
% Of Pretax Income	29.63%	-15.39%
Net Earnings	$32.30M	$23.72M	-$112.4M
YoY Change	-128.75%	-138.25%	47.69%
Net Earnings / Revenue	6.53%	5.54%	-50.08%
Basic Earnings Per Share	$0.05	$0.04
Diluted Earnings Per Share	$0.05	$0.04	-$180.5K
COMMON SHARES
Basic Shares Outstanding	670.0M shares	640.7M shares	665.6M shares
Diluted Shares Outstanding		640.7M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$72.20M	$36.30M	$85.50M
YoY Change	-15.56%	-43.89%	-11.4%
Cash & Equivalents	$72.21M	$36.29M	$85.45M
Short-Term Investments
Other Short-Term Assets	$5.309M	$7.542M	$15.84M
YoY Change	-66.48%	126.69%	311.72%
Inventory	$132.3M	$111.9M	$53.43M
Prepaid Expenses
Receivables	$286.3M	$241.5M	$134.6M
Other Receivables	$16.00M	$14.80M	$23.10M
Total Short-Term Assets	$523.2M	$428.1M	$324.0M
YoY Change	61.45%	46.19%	1.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$140.6M	$134.1M	$127.1M
YoY Change	10.58%	4.34%	-12.14%
Goodwill	$680.6M	$675.8M	$671.9M
YoY Change	1.29%	-2.87%	-4.04%
Intangibles
YoY Change
Long-Term Investments	$15.70M	$14.30M	$20.60M
YoY Change	-23.79%	23.28%	-32.24%
Other Assets	$10.06M	$5.857M	$6.888M
YoY Change	46.05%	5.95%	-4.62%
Total Long-Term Assets	$1.950B	$1.943B	$1.985B
YoY Change	-1.78%	-6.43%	-6.94%
TOTAL ASSETS
Total Short-Term Assets	$523.2M	$428.1M	$324.0M
Total Long-Term Assets	$1.950B	$1.943B	$1.985B
Total Assets	$2.473B	$2.371B	$2.309B
YoY Change	7.09%	0.07%	-5.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$100.9M	$65.69M	$62.54M
YoY Change	61.32%	-15.02%	31.95%
Accrued Expenses	$240.9M	$248.4M	$164.9M
YoY Change	46.05%	43.82%	-18.96%
Deferred Revenue	$15.78M	$14.10M	$19.20M
YoY Change	-17.78%	-54.45%	-69.77%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$27.20M	$15.00M	$12.40M
YoY Change	119.35%	47.06%	111.93%
Total Short-Term Liabilities	$375.5M	$335.9M	$249.1M
YoY Change	50.72%	24.34%	-13.6%
LONG-TERM LIABILITIES
Long-Term Debt	$3.837M	$4.010M	$3.906M
YoY Change	-1.77%	-1.98%	-16.07%
Other Long-Term Liabilities	$37.07M	$45.03M	$87.80M
YoY Change	-57.78%	-59.78%	-55.87%
Total Long-Term Liabilities	$426.0M	$411.6M	$445.4M
YoY Change	-4.35%	-10.02%	19.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$375.5M	$335.9M	$249.1M
Total Long-Term Liabilities	$426.0M	$411.6M	$445.4M
Total Liabilities	$801.5M	$747.5M	$694.5M
YoY Change	15.41%	2.74%	5.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.482B	-$1.514B	-$1.511B
YoY Change	-1.94%	8.25%	26.23%
Common Stock	$6.706M	$6.706M	$6.704M
YoY Change	0.03%	8.83%	14.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.791M	$1.791M	$1.791M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	549.9K shares	549.9K shares	549.9K shares
Shareholders Equity	$1.672B	$1.624B	$1.615B
YoY Change
Total Liabilities & Shareholders Equity	$2.473B	$2.371B	$2.309B
YoY Change	7.09%	0.07%	-5.79%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q4
OPERATING ACTIVITIES
Net Income	$32.30M	$23.72M	-$112.4M
YoY Change	-128.75%	-138.25%	47.69%
Depreciation, Depletion And Amortization	$20.10M	$21.04M	$22.50M
YoY Change	-10.67%	-11.63%	-5.86%
Cash From Operating Activities	$34.30M	$63.00M	-$46.00M
YoY Change	-174.57%	-363.6%	32.95%
INVESTING ACTIVITIES
Capital Expenditures	-$6.800M	-$9.800M	-$3.800M
YoY Change	78.95%	292.0%	22.58%
Acquisitions
YoY Change
Other Investing Activities	$100.0K	$15.20M	$100.0K
YoY Change	0.0%	4966.67%	0.0%
Cash From Investing Activities	-$6.700M	$5.500M	-$3.800M
YoY Change	76.32%	-350.0%	31.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.100M	-54.50M	70.60M
YoY Change	-88.53%	172.5%	-22.16%
NET CHANGE
Cash From Operating Activities	34.30M	63.00M	-46.00M
Cash From Investing Activities	-6.700M	5.500M	-3.800M
Cash From Financing Activities	8.100M	-54.50M	70.60M
Net Change In Cash	35.70M	14.00M	20.80M
YoY Change	71.63%	-130.37%	-60.9%
FREE CASH FLOW
Cash From Operating Activities	$34.30M	$63.00M	-$46.00M
Capital Expenditures	-$6.800M	-$9.800M	-$3.800M
Free Cash Flow	$41.10M	$72.80M	-$42.20M
YoY Change	-197.39%	-440.19%	33.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000944809
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201613Member
CY2018	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201807Member
CY2018	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.01
CY2018Q3	opk	Number Of Derivative Lawsuits NumberOfDerivativeLawsuits	12	lawsuit
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:PropertyPlantAndEquipmentNet
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33528
	dei	Entity Registrant Name EntityRegistrantName	OPKO Health, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-2402409
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4400 Biscayne Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33137
	dei	City Area Code CityAreaCode	(305)
	dei	Local Phone Number LocalPhoneNumber	575-4100
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	OPK
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	670000024	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36294000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85452000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	241544000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	134617000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	111873000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	53434000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38398000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50542000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	428109000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	324045000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	134102000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127111000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	486418000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	528962000	USD
CY2020Q3	opk	In Process Researchand Development InProcessResearchandDevelopment	590200000	USD
CY2019Q4	opk	In Process Researchand Development InProcessResearchandDevelopment	590200000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	675795000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	671940000	USD
CY2020Q3	us-gaap	Long Term Investments LongTermInvestments	14325000	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	20746000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36485000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39380000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5857000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6888000	USD
CY2020Q3	us-gaap	Assets Assets	2371291000	USD
CY2019Q4	us-gaap	Assets Assets	2309272000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	65685000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	62537000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	248422000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	164925000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9080000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	694513000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12038000	USD
CY2020Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	12702000	USD
CY2019Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	9619000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	335889000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	249119000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28225000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27665000	USD
CY2020Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	219194000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	211208000	USD
CY2020Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	119182000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	118717000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	45031000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	87804000	USD
CY2020Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	411632000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	445394000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	747521000	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	670550201	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	670378701	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	6706000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	6704000	USD
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	549907	shares
CY2020Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	549907	shares
CY2020Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1791000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1791000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3150437000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3142993000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17451000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-22070000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1514131000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1511077000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1623770000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1614759000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2371291000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2309272000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	428064000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	228772000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	940739000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	677592000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	99897000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	80542000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	253749000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	264175000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18493000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30017000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57862000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	94832000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1083000	USD
CY2019Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1109000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1334000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-78000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13879000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16412000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43753000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49393000	USD
CY2020Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	655000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	406125000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	267783000	USD
	us-gaap	Operating Expenses OperatingExpenses	932381000	USD
	us-gaap	Operating Expenses OperatingExpenses	839180000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	21939000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-39011000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	8358000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-161588000	USD
CY2020Q3	opk	Interest Income Nonoperating InterestIncomeNonoperating	1000	USD
CY2019Q3	opk	Interest Income Nonoperating InterestIncomeNonoperating	350000	USD
	opk	Interest Income Nonoperating InterestIncomeNonoperating	149000	USD
	opk	Interest Income Nonoperating InterestIncomeNonoperating	1477000	USD
CY2020Q3	opk	Interest Expense Nonoperating InterestExpenseNonoperating	5544000	USD
CY2019Q3	opk	Interest Expense Nonoperating InterestExpenseNonoperating	5792000	USD
	opk	Interest Expense Nonoperating InterestExpenseNonoperating	16514000	USD
	opk	Interest Expense Nonoperating InterestExpenseNonoperating	16048000	USD
CY2020Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-496000	USD
CY2019Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-21000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	112000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	6000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4749000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15470000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10637000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20367000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1290000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20933000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5616000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-34932000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	20649000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-59944000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2742000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-196520000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3178000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1769000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4021000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3636000	USD
CY2020Q3	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	23827000	USD
CY2019Q3	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	-61713000	USD
	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	-1279000	USD
	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	-200156000	USD
CY2020Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-110000	USD
CY2019Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-294000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-433000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2419000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	23717000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-62007000	USD
	us-gaap	Profit Loss ProfitLoss	-1712000	USD
	us-gaap	Profit Loss ProfitLoss	-202575000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.04
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	640699982	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	586351045	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	640619485	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	586348791	shares
CY2020Q3	us-gaap	Profit Loss ProfitLoss	23717000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-62007000	USD
	us-gaap	Profit Loss ProfitLoss	-1712000	USD
	us-gaap	Profit Loss ProfitLoss	-202575000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	8301000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8423000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4619000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8643000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	32018000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-70430000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	2907000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-211218000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1588343000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2740000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	669000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	23717000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	8301000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1623770000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1614759000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6777000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	669000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1712000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4619000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1623770000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1708931000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3428000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-62007000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8423000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1641929000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1791291000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11007000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-3000	USD
	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	50852000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-202575000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8643000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1641929000	USD
	us-gaap	Profit Loss ProfitLoss	-1712000	USD
	us-gaap	Profit Loss ProfitLoss	-202575000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	65295000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	71281000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	7639000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	4558000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	626000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	506000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-433000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2419000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6777000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11007000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	10172000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1455000	USD
	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	-1253000	USD
	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	-17178000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1334000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-78000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	655000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1974000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2065000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	107255000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3257000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	60565000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9543000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13111000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2556000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	270000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-240000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3261000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	30597000	USD
	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	-782000	USD
	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	147000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4717000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-56860000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	88988000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-238000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5218000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-126485000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1200000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	15110000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	192000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	552000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	26885000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	8866000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11583000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9514000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	200293000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	7762000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	669000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	-3000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	699079000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	99353000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	742932000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	158477000	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	28800000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-43184000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	104604000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	391000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-411000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49158000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31806000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85452000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96473000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36294000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64667000	USD
	us-gaap	Interest Paid Net InterestPaidNet	10657000	USD
	us-gaap	Interest Paid Net InterestPaidNet	11084000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	148000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3103000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	35826000	USD
	opk	Operating Lease Liability Initial Recognition Upon Adoption OperatingLeaseLiabilityInitialRecognitionUponAdoption	0	USD
	opk	Operating Lease Liability Initial Recognition Upon Adoption OperatingLeaseLiabilityInitialRecognitionUponAdoption	36239000	USD
	opk	Common Stock Warrants Net Exercised CommonStockWarrantsNetExercised	0	USD
	opk	Common Stock Warrants Net Exercised CommonStockWarrantsNetExercised	20000	USD
	opk	Numberof Sales Employees NumberofSalesEmployees	300	employee
CY2020Q3	opk	Covid19 Percent Of Total Test Volume COVID19PercentOfTotalTestVolume	0.63
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</span>
	us-gaap	Inventory Write Down InventoryWriteDown	3400000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	1400000	USD
CY2020Q3	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1800000000	USD
CY2019Q4	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1800000000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	675800000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	671900000	USD
CY2019Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1100000000	USD
CY2020Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1100000000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43800000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49400000	USD
	us-gaap	Depreciation Depreciation	21500000	USD
	us-gaap	Depreciation Depreciation	21900000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of credit risk and allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span>While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000000.0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1900000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	300000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	300000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6800000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11000000.0	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	171500	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	171500	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	171500	shares
CY2020Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	171500	shares
CY2020Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	171500	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	171500	shares
CY2020Q3	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
CY2019Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	0	shares
CY2019Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	0	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	24877	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	19232	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	24877	shares
	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	5645	shares
CY2020Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	243540000	USD
CY2019Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	136551000	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1996000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1934000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	241544000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	134617000	USD
CY2020Q3	us-gaap	Other Inventory Supplies OtherInventorySupplies	72518000	USD
CY2019Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	23005000	USD
CY2020Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	30268000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	25142000	USD
CY2020Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	6425000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3238000	USD
CY2020Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	6343000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4586000	USD
CY2020Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3681000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2537000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	111873000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	53434000	USD
CY2020Q3	opk	Taxes Recoverable Current TaxesRecoverableCurrent	14072000	USD
CY2019Q4	opk	Taxes Recoverable Current TaxesRecoverableCurrent	19808000	USD
CY2020Q3	us-gaap	Supplies Supplies	9435000	USD
CY2019Q4	us-gaap	Supplies Supplies	8147000	USD
CY2020Q3	us-gaap	Prepaid Insurance PrepaidInsurance	6635000	USD
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3486000	USD
CY2020Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	714000	USD
CY2019Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3262000	USD
CY2020Q3	us-gaap	Other Assets Current OtherAssetsCurrent	7542000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	15839000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38398000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50542000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	342414000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	298234000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	486418000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	528962000	USD
CY2020Q3	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	84768000	USD
CY2019Q4	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	13751000	USD
CY2020Q3	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	22669000	USD
CY2019Q4	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	38635000	USD
CY2020Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	37671000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	33671000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	14099000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	19196000	USD
CY2020Q3	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	5912000	USD
CY2019Q4	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	8122000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2374000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2375000	USD
CY2020Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2343000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2743000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5340000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1333000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	73246000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	45099000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	248422000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	164925000	USD
CY2020Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	0	USD
CY2019Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	44749000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	8643000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7308000	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4010000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3906000	USD
CY2020Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2538000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4046000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2951000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2571000	USD
CY2020Q3	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	26889000	USD
CY2019Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	25224000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	45031000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	87804000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	671940000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	3855000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	675795000	USD
CY2020Q3	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	496000	USD
CY2020Q3	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	2374000	USD
CY2020Q3	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	1036000	USD
CY2020Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	12720000	USD
CY2020Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	35000	USD
CY2020Q3	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	38000	USD
CY2020Q3	us-gaap	Long Term Investments LongTermInvestments	14325000	USD
CY2020Q3	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	6200000	USD
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	8959000	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	10324000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1365000	USD
CY2019Q4	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	11	institution
CY2020Q3	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	11	institution
CY2020Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	100974000	USD
CY2020Q3	us-gaap	Line Of Credit LineOfCredit	10993000	USD
CY2019Q4	us-gaap	Line Of Credit LineOfCredit	52077000	USD
CY2020Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	12720000	USD
CY2020Q3	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	38000	USD
CY2020Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	12929000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11017000	USD
CY2020Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	11017000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	18870000	USD
CY2019Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	120000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	19123000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9683000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	9683000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11000000.0	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9700000	USD
CY2020Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	62000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	156000	USD
CY2019Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	160000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11000000.0	USD
	opk	Number Of Class Action Lawsuits NumberOfClassActionLawsuits	2	lawsuit
CY2018Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	100000	USD
CY2020Q1	opk	Payments For Overpayment Finding PaymentsForOverpaymentFinding	576332	USD
CY2020Q3	us-gaap	Purchase Obligation PurchaseObligation	196100000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	1600000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	25800000	USD
CY2020Q3	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	21400000	USD
CY2019Q4	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	27300000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	21767000	USD
CY2020Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17050000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	18376000	USD
CY2017Q4	opk	Proceeds From Development And License Agreement Upfront Payment ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment	6000000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	USD
	opk	Collaborative Arrangement License Termination Written Notice Threshold CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold	P3M
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	21939000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-39011000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	8358000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-161588000	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21036000	USD
CY2019Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23805000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	65295000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	71281000	USD
CY2020Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-110000	USD
CY2019Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-294000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-433000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2419000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	428064000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	228772000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	940739000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	677592000	USD
CY2020Q3	us-gaap	Assets Assets	2371291000	USD
CY2019Q4	us-gaap	Assets Assets	2309272000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	675795000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	671940000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36485000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39380000	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	4880000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6789000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9080000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12038000	USD
CY2020Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2343000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2743000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28225000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27665000	USD
CY2020Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2538000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4046000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2020Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063
CY2020Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.043
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.030
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3154000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	731000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7737000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2242000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6777000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	1218000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5996000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	620000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4788000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	277000	USD
CY2020Q3	opk	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	17384000	USD
CY2020Q3	opk	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	1000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	45836000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	5089000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8531000	USD
CY2020Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	208000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	37305000	USD
CY2020Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	4881000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	13700000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2300000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	2300000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	15300000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2300000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	2600000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	13596000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	15664000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	149000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	306000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2009000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2165000	USD
	opk	Payments For Leases PaymentsForLeases	15754000	USD
	opk	Payments For Leases PaymentsForLeases	18135000	USD

Files In Submission

Name	View Source	Status
0000944809-20-000039-index-headers.html	Edgar Link	pending
0000944809-20-000039-index.html	Edgar Link	pending
0000944809-20-000039.txt	Edgar Link	pending
0000944809-20-000039-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opk-20200930.htm	Edgar Link	pending
opk-20200930.xsd	Edgar Link	pending
opk-20200930_cal.xml	Edgar Link	unprocessable
opk-20200930_def.xml	Edgar Link	unprocessable
opk-20200930_htm.xml	Edgar Link	completed
opk-20200930_lab.xml	Edgar Link	unprocessable
opk-20200930_pre.xml	Edgar Link	unprocessable
opk-9302020xex311.htm	Edgar Link	pending
opk-9302020xex312.htm	Edgar Link	pending
opk-9302020xex321.htm	Edgar Link	pending
opk-9302020xex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2020 Q4 Form 10-Q Financial Statement

#000094480920000039 Filed on October 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2020 Q4 Form 10-Q Financial Statement

#000094480920000039 Filed on October 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk